
|Articles|May 1, 2003
Corticosteroid shown to be safe for long-term SAC control
Author(s)Charles Slonim, MD, Chet Scerra
Tampa, FL-Loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb Pharmaceuticals and Pharmos Corp.), the first corticosteroid specifically designed for signs and symptoms of seasonal allergic conjunctivitis (SAC), is safe for long-term use, according to a recent multicenter study.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
2
ARPA-H funds tear-duct biosensor system for dry eye, systemic disease
3
First patient dosed in phase 3 pivotal cohort of LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis
4
NCX 470 gains positive regulatory feedback in China ahead of US NDA submission
5


























